Investigational headworn wearable delivering calibrated vestibular stimulation to treat vestibular migraine and chronic vertigo.
The Otolith device is a non-invasive, headworn wearable medical device that delivers the company's patented non-invasive Vestibular Resonance Therapy (nVRT) through precisely calibrated vibrations applied to the vestibular system. It is being developed as a prescription treatment for vestibular migraine and chronic vertigo, and it has received FDA Breakthrough Device designation. The device remains investigational while the company pursues FDA marketing authorization through the De Novo pathway.
It has been studied by more than five hundred participants with no reported serious device-related adverse events, across indications that include vestibular migraine, motion sensitivity, tinnitus, and virtual-reality sickness. Clinical trial registries list the device under the name OtoBand, including the VIBRANT-VM vestibular migraine study.
Adds products that compete with one of Vestibular Migraine Treatment Wearable’s direct competitors but not with Vestibular Migraine Treatment Wearable itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Vestibular Migraine Treatment Wearable | Cefaly | gammaCore | Nerivio | |
|---|---|---|---|---|---|
| Provider | |  |  |  | |
| Founded | 2015 | 2004 | 2005 | 2016 | |
| Sells To | Consumers | Consumers | B2G | Patients | |
| Pricing Model | Recurring | E-commerce | Recurring, Transactional | — | |
| Ownership | Venture-backed | Private | Public | Private |
Provider
Founded 2015
Sells To Consumers
Pricing Model Recurring
Ownership Venture-backed
Provider
Founded 2004
Sells To Consumers
Pricing Model E-commerce
Ownership Private
Provider
Founded 2005
Sells To B2G
Pricing Model Recurring, Transactional
Ownership Public
Provider
Founded 2016
Sells To Patients
Pricing Model —
Ownership Private
